Cellosaurus cell line 306D326.26 (CVCL

Cellosaurus 306D326.26 (CVCL_B0UY)

Cross-references
Cell line name	306D326.26
Synonyms	LT1002; Sphingomab
Accession	CVCL_B0UY
Resource Identification Initiative	To cite this cell line use: 306D326.26 (RRID:CVCL_B0UY)
Comments	Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized sonepcizumab (LT1009; Asonex) therapeutic antibody candidate for treatment of patients with cancer or ocular diseases. Monoclonal antibody isotype: IgG1, kappa. Monoclonal antibody target: ChEBI; CHEBI_37550; Sphingosine 1-phosphate (S1P).
Species of origin	Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Category	Hybridoma
Publications	PubMed=19509417; DOI=10.1194/jlr.M900048-JLR200; PMCID=PMC2759830 Nicole O'Brien, S. Tarran Jones, David G. Williams, H. Brad Cunningham, Kelli Moreno, Barbara Visentin, Angela Gentile, John Vekich, William Shestowsky, Masao Hiraiwa, Rosalia Matteo ...Show all 17 authors... , Amy Cavalli, Douglas Grotjahn, Maria Grant, Genevieve Hansen, Mary-Ann Campbell, Roger Allen Sabbadini; Show fewer authors Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J. Lipid Res. 50:2245-2257(2009) Patent=US9163091 Roger Allen Sabbadini, William A. Garland, Genevieve Hansen, James Stephen Swaney, Rosalia Matteo, Gordon B. Mills, Jonathan Michael Wojciak; Compositions and methods for binding lysophosphatidic acid. Patent number US9163091, 20-Oct-2015
Cell line collections (Providers)	ATCC; SD-5362 - Discontinued
Encyclopedic resources	Wikidata; Q108819537
Entry history
Entry creation	23-Sep-2021
Last entry update	19-Dec-2024
Version number	6